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Abstract There is increasing evidence of Helicobacter
pylori (H. pylori) resistance to the classical triple therapy
consisting of a proton-pump inhibitor and clarithromycin
with either amoxicillin or metronidazole. This study is
aimed at establishing the efficacy and safety of a 14-day
regimen to eradicate H. pylori in patients who have failed
with the classical triple therapy given for 14 days. One
hundred seventy-six patients diagnosed to have H. pylori
infection were given triple therapy for 14 days. Fifty-two
patients who failed to respond as evident from positive
14C-urea breath test (UBT) done 4–6 weeks after the
completion of triple therapy were offered a combination
regimen comprised of furazolidone 200 mg b.i.d, co-am-
oxiclav 1 g b.i.d., colloidal bismuth subcitrate 240 mg
b.i.d., and esomeprazole 40 mg b.i.d. for 14 days. The
mean age of these patients was 41 ± 13 years (range 20–
67). Thirty-four were males. To document eradication of H.
pylori, UBT was repeated 4 weeks after the completion of
treatment. On an intention-to-treat analysis, the eradication
rate was 81% (42 out of 52) whereas on per-protocol basis,
the eradication rate was 82.4% (42 out of 51). In conclu-
sion, this new regimen represents a suitable second-line
therapy.
Keywords Helicobacter pylori  Clarithromycin 
Furazolidone  Co-amoxiclav  Bismuth  Esomeprazole
Introduction
Triple therapy, a combination of proton-pump inhibitor
(PPI) with two antibiotics, remains the recommended first
choice anti-Helicobacter pylori (H. pylori) treatment. The
usual antibiotics used are clarithromycin and amoxicillin
or metronidazole [1]. However, there is an increasing
evidence of H. pylori resistance to classical triple therapy
[2–5]. Increasing resistance to clarithromycin and metro-
nidazole is being documented as leading to failure of
standard eradication regimes [3, 4]. Amoxicillin-resistant
H. pylori have also been reported [5]. Another reason for
failure is low patient compliance with this treatment due to
side effects [6]. Clarithromycin, metronidazole, and
amoxicillin used in therapy may cause several side effects
such as nausea, vomiting, metallic taste in the mouth,
diarrhea, headache, dizziness, and yeast infections in
women. A regimen useful in one geographical area may
not be effective or practical in another area. Bismuth-
containing quadruple therapy with a PPI, bismuth subci-
trate, metronidazole, and tetracycline given for 2 weeks
may be a first choice treatment option in an era of increased
clarithromycin resistance [1, 2]. The best first-line and re-
treatment regimens have yet to be established.
It has been reported that the amoxicillin-clavulanate
combination has a higher activity than amoxicillin alone
against H. pylori [5, 7]. Furazolidone has also been used in
the first-line and rescue regimens [8, 9]. It is an antimicrobial
agent that is both available and inexpensive in developing
countries. It has been used in China for more than 20 years in
the treatment of peptic ulcer as the single therapeutic agent,
with healing rates comparable to those obtained with
cimetidine and displaying lower recidivating rates [10]. The
combination therapy with furazolidone, amoxicillin-cla-
vulanate (co-amoxiclav), bismuth compound, and a PPI may
This study was conducted under ClinicalTrials.gov number
NCT00520949.
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represent an effective therapeutic scheme for the treatment
of resistant H. pylori infection. It is expected to be better
tolerated than clarithromycin-based regimens and effective
in the re-treatment for H. pylori infection. This study was
aimed at establishing the efficacy and safety of a 14-day
regimen using the above drugs to eradicate H. pylori in
patients who have failed with the classical triple therapy
given for 14 days.
Materials and Methods
Patients
In this prospective, open study, performed between Octo-
ber 2006 and May 2008, we enrolled 176 patients from our
gastroenterology clinic who were diagnosed with H. pylori
infection and had associated endoscopic gastritis, peptic
ulcer, or gastroesophageal reflux disease. Informed written
consent was obtained from each patient before entering the
trial. Exclusion criteria were evidence of any malignancy,
gastric outlet syndrome, history of gastric surgery, chronic
liver disease, severe chronic renal failure, or any major co-
morbidity, and known or suspected hypersensitivity to the
medication used in the study. Complete history was taken
including present and past history of illness, medications,
smoking, and alcohol intake. Physical examination was
also performed. Hematological and biochemical tests
including complete blood count, blood urea nitrogen,
serum creatinine, and liver function tests were carried out.
Diagnosis of H. pylori infection was made on the basis of
any two out of three positive tests, i.e., 14C-urea breath test
(UBT), rapid urease test, or histology on gastric biopsies
obtained at endoscopy, two each from both antrum and
body. UBT was done with the Heliprobe System (Noster
AB, Sweden) and read as described by the manufacturer:
0—patient not infected, I—borderline result, II—patient
infected [11]. For the rapid urease test, Pronto Dry (Med-
ical Instrument Corp., France) was used with two biopsies,
one each from the antrum and corpus and read at 30 min
[12]. Hematoxylin and eosin stain was used for the detec-
tion of H. pylori. In doubtful cases Giemsa staining was
carried out to ascertain presence of H. pylori. These
patients were given a classical triple regimen of amoxicillin
1 g, clarithromycin 500 mg, and omeprazole 20 mg twice
a day for 14 days. Eradication of H. pylori was docu-
mented by repeat UBT performed 4 weeks after
completion of therapy. Patients who failed to eradicate H.
pylori were recruited for a new combination protocol
(n = 52). This furazolidone and bismuth-based regimen
was comprised of co-amoxiclav (Augmentin, GSK) 1 g
b.i.d., furazolidone (Furoxone, GSK) 200 mg b.i.d., col-
loidal bismuth subcitrate (Cebes-S, Adamjee) 240 mg
b.i.d., and PPI esomeprazole (Nexum, Getz Pharma) 40 mg
b.i.d. for 14 days. All patients were evaluated at the end of
treatment for compliance with drugs and related adverse
effects during the treatment. To improve the compliance all
patients were warned of possible side effects beforehand.
Therapeutic success was again evaluated by UBT 4 weeks
after the completion of treatment (Fig. 1). The study was
approved by the ethics committee of the hospital.
Statistical Analysis
Statistical calculations were performed with the SPSS
statistics software, version 10.0 (SPSS Inc., Chicago,
USA). Results were presented as mean ± standard devia-
tion for quantitative variables and numbers and percentages
for qualitative variables. All patients were evaluated in an
intention-to-treat (ITT) analysis, in which patients without
final H. pylori determination or with protocol violations
were considered treatment failures. The per-protocol (PP)
analysis included all subjects who took at least 80% of each
study medication as prescribed and completed the final H.
pylori status assessment.
Sample Size
Assuming 90% effectiveness for eradication of H. pylori
infection in the study population with 95% confidence level
and a bound on error of ±8.5%, the estimated sample size
was 48 subjects for quadruple therapy; however, for stan-
dard triple therapy the response rate for eradication of H.
pylori infection was expected to be 75%, thus we took
















Fig. 1 Summary of the study
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Results
One hundred seventy-six patients were enrolled for triple
therapy over a period of 20 months. In ITT analysis,
eradication was achieved in 119 (68%) patients. In 52
patients who failed to respond, the new combination ther-
apy as described above was commenced. The mean age of
patients who received this therapy was 41 ± 13 years
(range 20–67). Thirty-four were males with male to female
ratio of 2:1.
Efficacy
All patients completed the study with one exemption
where follow-up UBT could not be done. H. pylori
eradication was achieved in 42 (81%) out of 52 by ITT
analysis and 42 of 51 (82.4%) by PP analysis (Table 1).
The mean age of our patients receiving both triple and
furazolidone-based therapy was only 41 years. The failure
of triple therapy was present in 34% of the patients
between 31 and 50 years of age (P = 0.05). However, in
the same age group, new combination therapy failed in
26% of the patients, which is not different from other age
groups (P = 0.33).
Safety
The most frequent side effects were nausea and metallic
taste in the mouth experienced by 26 (50%) and 11 (21%)
patients, respectively (Table 2). However, side effects were
mild and well tolerated.
Discussion
H. pylori infection is the main cause of gastritis, gastro-
duodenal ulcer, and gastric cancer and is considered a
major public health issue. Factors influencing success or
failure of an anti-H. pylori regimen include patient’s
compliance, antimicrobial resistance, and duration of
therapy [2]. The most effective recommended regimen,
i.e., a PPI with two antimicrobials such as amoxicillin,
clarithromycin, or metronidazole, fails to eradicate
infection in more than 20% of the compliant patients [2,
13, 14]. Therefore, appropriate selection of the patients
and choice of antibiotics are of major importance for the
treatment outcome [15, 16]. Third world countries have
large populations with low socioeconomic levels and
high bacterial resistance to antibiotics. However, the
incidence of clarithromycin-resistant strains of H. pylori
is increasing throughout the world [17, 18]. We have
previously reported high prevalence of clarithromycin
resistance among our patients with H. pylori infection
[19].
In a previous multicenter study done in patients with
documented active duodenal ulcer, 1-week triple therapy
with PPI, amoxicillin, and clarithromycin gave an eradi-
cation rate of 62% with ITT analysis in a group of
patients recruited from Pakistan [20]. In our study, we had
a 32% failure rate of triple therapy to eradicate H. pylori
infection despite giving it for 2 weeks. The low eradica-
tion rate might be attributed to several factors including
the majority of patients having non-ulcer dyspepsia,
comparatively younger age group, and antibiotic resis-
tance. A previous study has described a higher resistance
to clarithromycin in non-ulcer dyspeptic patients in
comparison to duodenal ulcer patients [21]. Macrolides
and amoxicillin are commonly prescribed in the com-
munity practice for various conditions including the
treatment of upper and lower respiratory tract infection. It
is known that the macrolide group of antibiotics display
cross-resistance. The practice of self-prescription of
medications in the community for minor ailments also
contributed to resistance [22]. The mean age of our
patients receiving both triple and new combination




Age (mean ± SD) 41 ± 13
Gender (M:F), number (%) 33 (65%):19 (35%)
Endoscopic findings, number (%)
Gastritis 47 (90%)
Gastroesophageal reflux disease 4 (8%)
Peptic ulcer 1 (2%)
14C-UBT post-triple therapy, number (%)
Positive 9 (17%)
Negative 42 (81%)
Not done 1 (2%)
Eradication rate, number (%)
ITT 42 (81%)
PP 43 (83%)
UBT 14C-urea breath test, ITT intention-to-treat, PP per-protocol
Table 2 Side effects of the second-line therapy (n = 52)
Side effect Number of patients (%)
Nausea 26 (50%)
Dark stool 26 (50%)
Heart burn 5 (10%)
Metallic taste in the mouth 11 (21%)
Reduced appetite 2 (4%)
Weakness 1 (2%)
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therapy was only 41 years. The failure rate of triple
therapy was 34% of the patients between 31 and 50 years
of age (P \ 0.05). This is consistent with a previous study
showing an increase bacterial load associated with
younger age group is not easily eradicated [15]. However,
in the same age group, new combination second-line
therapy was more effective, as it failed in 26% of patients
(P = 0.33).
On an ITT basis, the eradication rate with our combi-
nation therapy of furazolidone, colloidal bismuth
subcitrate, and co-amoxiclav with PPI achieved a higher H.
pylori eradication rate of 81% by ITT analysis and 83% by
PP analysis. The regimen was useful as second-line therapy
in our patients with high rate of triple therapy failure. We
used co-amoxiclav instead of amoxicillin, which was
already used in these patients when given triple therapy.
Moreover, co-amoxiclav is superior to amoxicillin in
eradicating H. pylori as it contains clavulanate potassium
which binds to bacterial beta-lactamases and prevents
break down of the amoxicillin molecule by bacteria that
would otherwise be resistant to it [5, 7]. The other drug
chosen in this regimen was furazolidone, which has been
used to treat peptic ulcer disease in China [10, 23]. The
efficacy of furazolidone in the treatment of peptic ulcer
disease is mainly due to its antibacterial activity against H.
pylori [24]. Furazolidone has been shown to be an efficient
component of first- and second-line and rescue therapies.
Buzas and Jozan [25] have reviewed the efficacy of fura-
zolidone-based therapies. Primary quadruple regimens
containing furazolidone were superior to triple therapies
with 83.5% eradication rate. Second-line schedules con-
taining furazolidone obtained an eradication rate of 76.1%.
The third drug used in our combination was a bismuth
compound, which does not have any resistance problem.
Treatment was given for 14 days based on the results of the
review suggesting the ‘longer the better’ [2, 25]. PPI was
also given twice a day to increase the local pH in the
microenvironment surrounding H. pylori to prevent phe-
notypic resistance [26]. The side effects associated with
new combination therapy were mild and well tolerated.
Adherence was good due to the low side effect profile and
well-motivated patients. This is in agreement with a meta-
analysis that showed the frequency of adverse effects for
furazolidone-based quadruple therapies was similar to
standard triple therapies [27].
In conclusion, the new regimen with furazolidone, co-
amoxiclav, bismuth compound, and PPI represent an
effective therapeutic scheme for the treatment of triple
therapy resistant H. pylori infection. It is reasonably well-
tolerated and is an effective second-line regimen for the re-
treatment of H. pylori infection. Higher efficacy of this
regimen is expected if used as a primary therapy.
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